Disease landscape

Multiple Myeloma clinical trials

Get alerts when Multiple Myeloma trials change

1,031 active trials 547 recruiting 122 Phase 3 393 sponsors 144 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 44 of 144 changes on 19 trials

2026-09-04
Recruitment suspended
Recruitment suspended: Enrollment to Dose Level 1 cohort has been met
NCT06232044 Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With… · Alliance for Clinical Trials in Oncology · Phase 1/2
2026-08-28
Primary completion pushed: 2029-10-30 → 2031-03-06
Recruitment opened
Completion pushed: 2029-10-30 → 2031-03-06
NCT07681596 A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With… · AstraZeneca · Phase 1/2
2026-09-05
Primary completion pushed: 2027-09 → 2028-03
Completion pushed: 2027-09 → 2028-03
NCT06262789 RAT-HEMATO : Return to Work After Malignant Hemopathy · University Hospital, Angers
2026-08-25
Primary completion pushed: 2026-05-31 → 2027-05-31
Completion pushed: 2027-03-31 → 2028-03-31
NCT06087653 Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in… · Starton Therapeutics, Inc · Phase 1/2
2026-09-04
Primary completion pushed: 2026-10-21 → 2027-10-21
Completion pushed: 2027-10-21 → 2028-10-21
NCT05208307 Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk… · Emory University · Phase 2
2026-08-14
Primary completion pushed: 2025-07-07 → 2026-03-11
NCT05675449 A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or… · Pfizer · Phase 1
2026-08-12
Primary completion pushed: 2026-06-30 → 2027-09-30
Primary endpoint(s) modified
Trial sites expanded: 11 → 14 locations
NCT06375044 Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma · Jiangsu Simcere Pharmaceutical Co., Ltd. · Phase 1
2026-09-01
Primary completion pushed: 2026-08-01 → 2027-12-01
NCT06138275 Elranatamab in R/R Multiple Myeloma · Massachusetts General Hospital · Phase 2
2026-09-01
Primary completion pushed: 2028-05 → 2028-10
Completion pushed: 2028-06 → 2028-11
NCT05874193 A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma · Cristiana Costa Chase, DO · Phase 2
2026-08-12
Primary completion pushed: 2026-03-01 → 2027-09-01
Completion moved earlier: 2029-09-01 → 2028-01-01
NCT04790474 Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for… · Tel-Aviv Sourasky Medical Center · Phase 2
2026-08-07
Primary completion pushed: 2026-08-31 → 2029-03-31
Recruitment opened
Completion pushed: 2026-08-31 → 2029-03-31
NCT07463807 Testing the Investigational Medication Combination of Teclistamab and Pomalidomide… · National Cancer Institute (NCI) · Phase 1/2
2026-08-28
Primary completion pushed: 2027-07-11 → 2027-12-31
Trial status changed: Recruiting → Not Yet Recruiting
Completion pushed: 2027-12-31 → 2028-12-31
NCT06429150 Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-08-28
Primary completion pushed: 2027-07-11 → 2028-12-31
Trial status changed: Recruiting → Not Yet Recruiting
Completion pushed: 2027-12-31 → 2029-12-31
NCT06435910 Engineered Dendritic Cell Vaccines for Multiple Myeloma · Shenzhen Geno-Immune Medical Institute · Phase 1
2026-08-25
Primary completion pushed: 2026-07 → 2027-06
Completion pushed: 2026-07 → 2027-06
NCT01297764 A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or… · Hackensack Meridian Health · Phase 1/2
2026-08-27
Primary completion pushed: 2026-09-30 → 2028-07-01
Trial status changed: Recruiting → Not Yet Recruiting
Completion pushed: 2026-12-31 → 2028-12-31
NCT06006741 Universal CAR-T Cells Targeting Multiple Myeloma · Shenzhen Geno-Immune Medical Institute · Phase 1
2026-08-11
Primary completion pushed: 2027-04-01 → 2027-09
Recruitment opened
Completion pushed: 2027-04-01 → 2027-09
NCT06262789 RAT-HEMATO : Return to Work After Malignant Hemopathy · University Hospital, Angers
2026-08-11
Primary completion pushed: 2026-07-11 → 2026-11-01
Completion pushed: 2026-07-11 → 2028-11-01
NCT04680468 Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and… · University of Pennsylvania · Phase 2
2026-08-08
Primary completion pushed: 2026-08-31 → 2028-08-31
NCT06066359 Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma · M.D. Anderson Cancer Center · Phase 1/2
2026-08-08
Primary completion pushed: 2025-10-30 → 2026-09-30
Completion pushed: 2026-04-30 → 2026-10-30
NCT05632380 ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple… · Institute of Hematology & Blood Diseases Hospital, China · Phase 1/2
2026-08-08
Primary completion pushed: 2026-08-31 → 2030-08-31
Completion pushed: 2026-08-31 → 2030-08-31
NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in… · M.D. Anderson Cancer Center · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-03 NCT07802717 A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169)… Vyriad, Inc. new Phase 1
2026-08-25 NCT07783607 MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma University of Vermont Medical Center new
2026-08-24 NCT07782944 CD38 Targeted -PET/ CT for Multiple Myeloma Guilin Medical University, China new
2026-08-20 NCT07776964 Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments… University of Minnesota new
2026-08-19 NCT07774988 Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma Can Lafci new
2026-08-18 NCT07771803 A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia… Roger Strair new Early Phase 1
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine new
2026-08-12 NCT07760454 A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma UCARsgen Biotech Limited new Phase 1/2
2026-08-07 NCT07751783 Development and Dissemination of Exercise Prescription and Intervention for Cancer… Kaohsiung Medical University Chung-Ho Memorial Hospital new
2026-07-31 NCT07740486 A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and… Polish Myeloma Consortium new Phase 3

Active trials by phase

Early Phase 1
49
Phase 1
163
Phase 1/2
116
Phase 2
272
Phase 2/3
12
Phase 3
110
Phase 4
18
Not charted: 291 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 1,031

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT05201781 A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel Janssen Research & Development, LLC Recruiting 2026-08-28
NCT07609940 Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of… Regeneron Pharmaceuticals Recruiting 2026-08-20
NCT07101445 Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the… Emory University Recruiting 2026-07-23
NCT07094048 Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager CHU de Quebec-Universite Laval Recruiting 2026-07-22
NCT06057402 Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) Pfizer Recruiting 2026-07-01
NCT05722405 Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of… Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting 2026-01-05
NCT06251076 Plan Development for Giving Teclistamab in the Outpatient Setting University Health Network, Toronto Recruiting 2025-12-10
NCT07025005 Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib… Tanta University Recruiting 2025-11-04
NCT06409702 Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease… The First Affiliated Hospital of Soochow University Recruiting 2025-06-12
NCT07030517 A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and… Johnson & Johnson Private Limited Active, Not Recruiting 2026-08-28
NCT07709884 A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly… The First Affiliated Hospital of Soochow University Not Yet Recruiting 2026-07-17
NCT07191379 Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma Odense University Hospital Not Yet Recruiting 2026-06-05
NCT07474961 BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. Anne Louise Tølbøll Sørensen Not Yet Recruiting 2026-03-16
NCT07334535 Isa-VRD in TIE HRMM Peking Union Medical College Hospital Not Yet Recruiting 2026-01-13
NCT03829371 STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION… University of Turin, Italy Active, Not Recruiting 2025-12-03
NCT07154537 Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) National Taiwan University Hospital Active, Not Recruiting 2025-09-04
NCT05944783 Bioequivalence Studies of Dasatinib 100 Mg Centro de Atencion e Investigacion Medica Not Yet Recruiting 2025-02-12
NCT05429515 Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury Peking Union Medical College Hospital Not Yet Recruiting 2022-06-23
Phase 3
NCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus… Celgene Recruiting 2026-09-02
NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… AstraZeneca Recruiting 2026-09-01
NCT05552222 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and… Janssen Research & Development, LLC Recruiting 2026-08-28
NCT07258511 A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3… Janssen Research & Development, LLC Recruiting 2026-08-28
NCT07518186 A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or… Janssen Research & Development, LLC Recruiting 2026-08-28
NCT05020236 A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in… Pfizer Recruiting 2026-08-24
NCT05623020 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… Pfizer Recruiting 2026-08-24
See all 1,031 active Multiple Myeloma trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (50) · Memorial Sloan Kettering Cancer Center (36) · Institute of Hematology & Blood Diseases Hospital, China (30) · Janssen Research & Development, LLC (28) · M.D. Anderson Cancer Center (21) · GlaxoSmithKline (20) · AbbVie (17) · Mayo Clinic (14) · Massachusetts General Hospital (13) · City of Hope Medical Center (12)

Get alerts when Multiple Myeloma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free